Pafolacianine

WEST LAFAYETTE, Ind., April 28, 2024 /PRNewswire/ -- Nicholas Baker, M.D., Director of Robotic Thoracic Surgery at the University of Pittsburgh Medical Center (UPMC) Passavant, presented key findings from independent research at the 104th Annual Meeting of the American Association for Thoracic Surgery (AATS) in Toronto, Canada. This is the first analysis of real-world experience for intraoperative molecular imaging (IMI) with CYTALUX following the phase 3 ELUCIDATE trial for cancer in the lung. The retrospective review included 39 sublobar resection procedures at UPMC that used CYTALUX to enhance the detection of cancer in the lung during surgery. "The real-world clinical outcome mirrors the experience reported by the investigators in the phase 3 trial and reinforces that this approach improves our ability to detect primary and metastatic pulmonary lesions," said Dr. Baker. The clinical outcome demonstrated an improvement in lung nodule localization, occult lesion identification and resection margin assessment, with CYTALUX aiding in the detection of primary lung cancer and metastatic lesions. The technology enabled the identification of 85.7% of primary lung cancer lesions compared to 67.9% identified using standard localization techniques without IMI. In addition, CYTALUX proved instrumental in identifying occult lesions intraoperatively that otherwise had no prior imaging correlates, revealing at least one additional malignancy in 18% of cases. "This technology represents a significant advancement over the way we have traditionally managed lung cancer in the operating room," said Ryan Levy, M.D., Chief of Thoracic Surgery at UPMC and co-author of the analysis shared at AATS. "The clinically proven ability to specifically target and visually detect occult and difficult-to-find lung lesions has dramatic implications for the way we approach and manage patients with lung cancer. I anticipate some of the biggest impact will be in patients with multifocal ground glass type cancers." CYTALUX was first approved as an adjunct for intraoperative identification of malignant lesions for use in adult patients with ovarian cancer in November 2021 and for adult patients with lung cancer in December 2022. CYTALUX is the first targeted molecular imaging agent that illuminates ovarian and lung cancer intraoperatively, enabling the detection of more cancer for removal. CYTALUX, administered by standard IV in as little as one hour before surgery, binds to folate receptors that are overexpressed in certain cancers1,2 and illuminates intraoperatively under near-infrared light. For more information about CYTALUX, visit CYTALUX.com. About On Target Laboratories, Inc. On Target Laboratories discovers and develops targeted intraoperative molecular imaging agents to illuminate cancer during surgery. Their molecular imaging technology, based on the pioneering work of Philip S. Low, PhD, Purdue University's Presidential Scholar for Drug Discovery and the Ralph C. Corley Distinguished Professor of Chemistry, is comprised of a near-infrared dye and a targeting molecule, or ligand, that binds to receptors overexpressed on cancer cells. The imaging agents illuminate the cancerous tissue, which may enable surgeons to detect more cancer that otherwise may have been left behind. CYTALUX, the company's first product, received FDA approval of a New Drug Application for ovarian cancer in November 2021 and a supplemental New Drug Application for lung cancer in December 2022. CYTALUX targets the folate receptors commonly found on many cancers, binds to the cancerous tissue, and illuminates under near-infrared light. A single dose of the agent is administered via intravenous infusion prior to surgery and assists surgeons in visually identifying additional cancerous tissue to be removed during the operation. For more information visit and . SOURCE On Target Laboratories, Inc.

WEST LAFAYETTE, Ind., Jan. 3, 2024 /PRNewswire/ -- On Target Laboratories, Inc., a privately held biotechnology company developing intraoperative molecular imaging agents to target and illuminate cancer during surgery, today announced the appointment of Scott Huennekens as Executive Chairperson of the Board. Continue Reading Scott Huennekens, Executive Chairperson of the Board, On Target Laboratories A 30-year veteran in the healthcare technology industry, Huennekens has played a pivotal role in more than 20 MedTech companies, including CEO, chairperson, board member, entrepreneur, and investor, with market valuations totaling over $30B and impacting greater than 20 million patient lives. He currently serves on the board of directors for multiple venture backed start-ups. "We are thrilled to welcome Scott to On Target Laboratories as the Executive Chairperson of the Board," said Ben Lundgren, President and CEO of On Target Laboratories. "His extensive experience and leadership in the healthcare industry make him an invaluable addition to our team. Scott's history in introducing novel, transformative technology into healthcare is ideally suited for our aspirations for On Target Laboratories." Mr. Huennekens expressed his enthusiasm for joining On Target Laboratories, stating, "I am honored to be part of On Target Laboratories, a company at the forefront of intraoperative molecular imaging. The work being done here has the potential to transform cancer surgery and make a significant impact on patient outcomes. I look forward to working with the talented team at On Target Laboratories and contributing to the company's continued success." About On Target Laboratories, Inc. On Target Laboratories discovers and develops targeted intraoperative molecular imaging agents to illuminate cancer during surgery. Their molecular imaging technology, based on the pioneering work of Philip S. Low, PhD, Purdue University's Presidential Scholar for Drug Discovery and the Ralph C. Corley Distinguished Professor of Chemistry, is comprised of a near-infrared dye and a targeting molecule, or ligand, that binds to receptors overexpressed on cancer cells. The imaging agents illuminate the cancerous tissue, which may enable surgeons to detect more cancer that otherwise may have been left behind. CYTALUX, the company's first product, received FDA approval of a New Drug Application for ovarian cancer in November 2021 and a supplemental New Drug Application for lung cancer in December 2022. CYTALUX targets the folate receptors commonly found on many cancers, binds to the cancerous tissue, and illuminates under near-infrared light. A single dose of the agent is administered via intravenous infusion prior to surgery and assists surgeons in visually identifying additional cancerous tissue to be removed during the operation. For more information visit and . SOURCE On Target Laboratories, Inc.